Bristol/Gilead HIV Combo Will Go To FDA In Mid-2006
This article was originally published in The Pink Sheet Daily
Executive Summary
The combination of Bristol’s Sustiva and Gilead’s Truvada would be the first complete HAART regimen available as a single once-daily tablet.
You may also be interested in...
Atripla Approved As First Once-Daily, Single-Tablet HIV Therapy
The Bristol/Gilead combination product will launch within seven business days.
Atripla Approved As First Once-Daily, Single-Tablet HIV Therapy
The Bristol/Gilead combination product will launch within seven business days.
Bristol/Gilead Joint Venture Targets 2005 Filing For HIV Fixed-Dose Combo
The joint venture is expected to use a new brand name for the fixed-dose combination of Sustiva and Truvada. Bristol and Gilead will receive sales revenues from the combination product “at percentages relative to the contribution represented by their individual products.”